La prolifération cellulaire et la croissance tissulaire sont étroitement contrôlées au cours du développement. Chez la Drosophila melanogaster, ces processus sont régulés en partie par la kinase stérile-20 Slik (SLK et LOK chez les mammifères) et le suppresseur de tumeur Hippo (Hpo, MST1/2 chez les mammifères) dans les cellules épithéliales. La surexpression de la kinase Slik augmente la taille des tissus chez les mouches adultes. Cependant, les mutants slik-/- meurent avant d'avoir terminé leur développement. Lorsqu’elle est surexprimée dans les cellules épithéliales des ailes en voie de développement, cette protéine favorise la prolifération cellulaire. En outre, l'expression de Slik dans une population de cellules conduit à une surprolifération des cellules voisines, même quand elles sont physiquement séparées. Ceci est probablement dû à la sécrétion de facteurs de croissance qui stimulent la prolifération de manière paracrine. En utilisant des méthodes génétiques et transcriptomiques, nous essayons de déterminer les molécules et les mécanismes impliqués. Contrairement à ce qui a été publié, nous avons constaté que Slik ne transmet pas de signal prolifératif en inhibant le suppresseur de tumeur Merlin (Mer, NF2 chez les mammifères), un composant en amont de la voie Hippo. Plutôt, elle favorise la prolifération non-autonome et la croissance des tissus en signalisation par la kinase dRaf (la seule kinase de la famille Raf chez la drosophile). Nous prouvons que dRaf est nécessaire chez les cellules voisines pour conduire la prolifération chez ces cellules. De plus, nous avons utilisé le séquençage du transcriptome pour identifier de nouveaux effecteurs en aval de Slik. Ce qui permettra de mieux comprendre les effets de SLK et LOK chez les humains. / Cell proliferation and tissue growth are tightly controlled during development. In epithelial tissues in Drosophila melanogaster, these processes are regulated in part by the Sterile-20 kinase Slik (SLK and LOK in mammals) and the tumor suppressor Hippo (Hpo, MST1/2 in mammals). Slik overexpression leads to an increase in tissue size in flies, whereas, slik-/- mutants die before completing development. Overexpressing this protein in the developing wing disc epithelium promotes cell proliferation, consistent with the overgrown wing phenotype in the adults. Moreover, expression of Slik in one population of cells leads to an overproliferation of neighboring cells, even when they are physically separated by a central lumen. This can be explained by secretion of paracrine growth factors, stimulating non-autonomous proliferation that is specific to Slik. We used genetic and transcriptomic assays to define the molecules and mechanism involved in Slik-mediated signaling. Contrary to what has been suggested, we found that Slik does not promote proliferation through the tumor suppressor Merlin (Mer, NF2 in mammals), an upstream component of the Hippo pathway, nor through other components of the Hippo pathway. Rather, Slik promotes non-autonomous proliferation and tissue growth signaling through dRaf (the single Raf family kinase orthologue in Drosophila). We found that dRaf is required in the signal receiving cells to stimulate proliferation. We performed RNA-seq to identify novel downstream effectors of Slik. Characterizing the signaling pathway downstream of Slik in Drosophila will shed light on how SLK and LOK function in mammals, and provide insights into their potential involvement during development and in cancer.

L'étude des interactions non-covalentes et des relations structure-fonction est à la base de la compréhension des systèmes biologiques. La MS supramoléculaire est une technique de choix pour l’étude des interactions protéine/protéine ou protéine/ligand. Dans le cadre d'études qualitatives ou quantitatives, pour chaque système étudié, les conditions expérimentales et les paramètres instrumentaux ont été optimisés pour conserver le complexe en phase gazeuse (1). L'objectif principal de ce travail est de caractériser le site nucléotidique de hPEBP1 et de contribuer à la découverte de molécules anti-métastases. Sur le plan fonctionnel, une activité enzymatique de hPEBP1 n'a pas pu être mise en évidence. Pour ce projet, une méthode MS de détermination de KD de complexes à faible affinité, plus précise et ne nécessitant par l'utilisation d'un ligand de référence a été développée (2). Une recherche des déterminants structuraux d'un ligand optimal de hPEBP1 a été réalisée par criblage de composés issus d’une synthèse raisonnée basée sur la structure des nucléotides FMN et GTP et par la détermination de leur KD (3). Les criblages ont montré que les critères structuraux indispensables pour la liaison sont la présence d’un groupement chargé ou donneur d’électrons, d’une structure apparentée à une base azotée et d’un cycle additionnel. Une part importante de l’affinité est liée au caractère hydrophobe du ligand. Certains ligands de synthèse ont montré une activité inhibitrice de l’invasion des lignées tumorales. / The study of noncovalent interactions and structure-function relationships provides the basis for the understanding of biological systems. Supramolecular MS is a favored technique to dissect protein/protein or protein/ligand interactions. In the context of qualitative or quantitative studies, experimental conditions and instrumental parameters have been optimized for each system to preserve the noncovalent complex in the gas-phase (1). The main objective of this work is to characterize the nucleotide site of hPEBP1 and to contribute to the discovery of antimetastatic molecules. Functionally, a catalytic activity for hPEBP1 could not be detected. For this project, an original MS method to more accurately determine KD for low-affinity complexes without a reference ligand was developed (2). Structural features of an optimal hPEBP1 ligand were determined by screening compounds based on FMN and GTP nucleotides in the context of a rational design approach, using KD determination to rank affinities (3). Screening highlighted that the essential structural requirements for binding hPEBP1 consist in a charged group or an electron donor, a structure related to a cyclic nitrogenous base and an additional cycle. A significant part of the affinity depends on the hydrophobic nature of the ligand. Some of the synthesized nucleotide analogs are active as inhibitors of invasion in tumor cell lines.

This project explores the intersection of postwar German history, visual art, and left-wing terrorism. More than thirty years have now passed since the German Red Army Faction’s (1970-1998) most spectacular violent campaign—the so-called “German Autumn” of 1977—and yet the organization continues to elicit a variety of cultural responses from many artists. Interestingly, many films, texts, and visual artworks featuring the Red Army Faction (RAF) as their subject focus heavily on the group’s charismatic founders and on the German state’s vigorous efforts to suppress them and their successors, and yet these works pay comparatively scant attention to the individuals whom the RAF murdered. In light of this observation, I argue that the German Left’s cultural memory of the RAF was and still is marked not only by a significant ambivalence concerning the RAF (especially the founders) and the German state, but also the victims. As a means of elucidating this ambivalence, I offer close “readings” of two works of visual art that debuted at different moments in the years following the German Autumn. Gerhard Richter’s October 18, 1977 (1988) is a photorealist series that invites viewers to consider the lives and especially the deaths of the RAF’s principal members, while Hans-Peter Feldmann’s photo compilation The Dead 1967-1993 (1998) presents a sobering chronology of individuals killed either directly or indirectly as a result of the German leftist counterculture, including terrorist violence, without making an immediate distinction between perpetrators and victims. Within the framework of the larger RAF cultural memory, the works of Richter and Feldmann thus help clarify some of the causes and effects of the German Left’s suspended resolution regarding RAF terrorism. / text

This examines the interplay of structure and local electrostatic fields in protein-protein and protein-solvent interactions. The partial charges of the protein amino acids and the polarization of the surrounding solvent create a complex system of electrostatic fields at protein-protein and protein-solvent interfaces. An approach incorporating vibrational Stark effect (VSE) spectroscopy, dissociation constant measurements, and molecular dynamics (MD) simulations was used to investigate the electrostatic interactions in these interfaces. Proteins p21Ras (Ras) and Rap1A (Rap) have nearly identical amino acid sequences and structures along the effector-binding region but bind with different affinities to Ral guanine nucleotide dissociation stimulator (RalGDS). A charge reversion mutation at position 31 alters the binding affinity of Ras and Rap with RalGDS from 0.1 [mu]M and 1 [mu]M, to 1 [mu]M and 0.5 [mu]M, respectively. A spectral probe was placed at various locations along the binding interface on the surface of RalGDS as it was docked with Ras and Rap single (position 30 or 31) and double mutants (both positions). By comparing the probes' absorption energies with the respective wild-type (WT) analogs, VSE spectroscopy was able to measure molecular-level electrostatic events across the protein-protein interface. MD simulations provided a basis for deconvoluting the structural and electrostatic changes observed by the probes. The mutation at position 31 was found to be responsible for both structural and electrostatic changes compared to the WT analogs. Furthermore, previous identification of positions N27 and N29 on RalGDS as "hot spots" that help discriminate between structurally similar GTPases was supported. The RalGDS probe-containing variants and three model compounds were placed in aqueous solvents with varying dielectric constants to measure changes in absorption energy. We investigated the ability of the Onsager solvent model to describe the solvent induced changes in absorption energy, while MD simulations were employed to determine the location and solvation of the probes at the protein-solvent interface. The solvent accessible-surface area, a measure of hydration, was determined to correlate well with the change in magnitude of the probe's absorption energy and the displaced solvent by the probe. / text

Thèse diffusée initialement dans le cadre d'un projet pilote des Presses de l'Université de Montréal/Centre d'édition numérique UdeM (1997-2008) avec l'autorisation de l'auteur.

During pregnancy, 4 - 7% of women suffer from major depressive disorder. When antidepressive treatment is needed, selective serotonin reuptake inhibitors (SSRIs) are the most commonly used. Although severe complications from SSRI treatment are rare, association with a number of adverse pregnancy and fetal outcomes has been found. Also, antenatal depression per se has been shown to affect pregnancy outcomes. The overall aim of this thesis was to examine the effects of SSRIs on human placenta and embryo. In the first study, gene expression was investigated in placenta from depressed, SSRI-treated and healthy pregnant women, using microarray analysis. Antenatal depression and SSRI treatment induced alterations in gene expression, but only 20 genes in common were noted. Validation with qRT-PCR showed that six out of seven selected genes were altered in SSRI-treated women compared with controls, and two genes were altered between depressed women and controls. In study two, the protein levels in placenta from depressed, SSRI-treated and healthy pregnant women were investigated, focusing on the NGF signaling pathway. NGF, phosphorylated Raf-1, ROCK2 and phosphorylated ROCK2, were altered in both SSRI-treated and depressed women, although the proteins were regulated differently in the two groups. In the third study, human embryos were treated with fluoxetine. Embryo development and protein expression were studied. Fluoxetine had some effect on the timing of embryo developmental stages. Also, several proteins were uniquely found in fluoxetine-treated embryos compared with untreated embryos. Fluoxetine also altered the levels of proteins secreted from the embryo. In the fourth study, the human neuroblastoma cell line SH-SY5Y/TrkA was treated with TPA and NGF. The activation of Raf-1 was investigated and the involvement of Ras and PKC was studied. Both NGF and TPA activated Raf-1, but to a different extent and via different pathways. The NGF-induced activation of Raf-1 was mediated via Ras, while TPA induced signaling via PKC. In conclusion, SSRI treatment and antenatal depression influence placental gene and protein expression. These findings may affect placental development and function, which in turn could affect fetal development. Also, direct exposure of embryos to fluoxetine has some effects on embryo development and protein expression, which may affect the development of the fetus.

Orientador: Maria José Soares Mendes Giannini / Banca: Christiane Pienna Soares / Banca: Paulo Inácio da Costa / Banca: Márcia de Souza Carvalho Melhem / Banca: Gil Bernard / Resumo: Neste trabalho foi realizado um estudo comparativo entre isolados de Pb18 e Pb265, que têm capacidades distintas de adesão às células Hela e Vero, sob influência da temperatura e diversos fatores químicos. Foram também avaliados eventos em células de epitélio pulmonar expostas à gp 43 e células de Pb18, antes e após inoculação animal, representando, respectivamente, isolados menos e mais virulentos. Os resultados mostram que as adesinas fúngicas são termo-lábeis, sugerindo sua natureza protéica. Os açúcares aminados glucosamina e galactosamina foram os mais eficientes para inibir a adesão celular, em relação à manose, glicose e galactose, indicando que esta atividade envolve mecanismos específicos tipo lectina. O estudo com componente da matriz extracelular mostrou que a laminina, assim como seus derivados sintéticos, inibiu a adesão do isolado Pb18, fato não verificado com Pb265, tanto com células Hela, quanto com a linhagem Vero, mas variável sob influência de fatores químicos. As distintas vias de sinalização foram demonstradas pelos eventos Ras-Raf, Rho e AKT verificados, sendo que o isolado menos virulento causou menos estresse citotóxico, comprovado por menor sinal Ras- Raf e AKT de proliferação. Os sinais intensos de proliferação observados nos experimentos com o isolado mais virulento e exposição à gp 43 poderiam ser associados à maior sobrevida do fungo que se internaliza mais facilmente nas células do hospedeiro, dificultando o seu reconhecimento por células do sistema monocítico-fagocitário, antes de causar apoptose, evadir e disseminar-se. A ativação das vias de sobrevida, associada a sinais citosólicos quando o Pb entra na célula epitelial, foi demonstrada de modo inédito neste trabalho. / Abstract: In this work it was accomplished a comparative study between isolates Pb18 and Pb265, which have distinct capacities of adhesion to the cells Hela and Vero under influence of temperature and several chemical factors. Events in pulmonary epithelial cells exposed to gp 43 and in Pb18 cells, before and after animal inoculation, representing, respectively, isolates less and more virulent were evaluated as well. The results show that the fungal adhesins are term-labels, suggesting its proteical nature. The aminated sugars glucosamine and galactosamine were the most efficient, in comparison with manose, glycose and galactose, in inhibiting the cellular adhesion, indicating that this activity involves specific mechanisms lectin-type. The study with extracellular matrix component indicated that the laminin, as well as its synthetic derivatives, inhibited the adhesion of the isolate Pb18 to the cells Vero and Hela, what did not occur with Pb265, but it was variable under influence of chemical factors. The distinct signaling pathways were demonstrated by the Ras-Raf, Rho and AKT events, considering that the less virulent isolate caused minor cytotoxic stress, proved by minor Ras-Raf and AKT proliferation signals. The intense proliferation signals observed in the experiments with more virulent isolate and exposition to gp 43 could be associated to larger time of survival of the fungus that more easily goes inside the host cells, making it difficult to the monocyte-macrophage system cells to recognize it before the apoptosis, the evasion and the dissemination. The Ras-Raf and AKT pathways acted synergetically with the effects of the cell survival. The decrease of the AKT event implied partial loss of the survival signal that intensified, following and in a opposite way, with Ras-Raf decrease. The activation of the survival pathways, associated to citosolic signals when Pb goes inside the epithelial cell, was for the first time demonstrated in this work. / Doutor

Les petites GTPases RAS alternent entre une forme inactive liée au GDP et une forme active liée au GTP. Ce mécanisme permet aux protéines RAS de transmettre les signaux des récepteurs se trouvant à la surface cellulaire vers divers réseaux de signalisation en aval. La protéine RAS joue un rôle important dans plusieurs fonctions biologiques, notamment la prolifération cellulaire, la survie cellulaire et même l'apoptose. Les mutations des gènes de la famille RAS sont retrouvées dans environ un tiers des tumeurs. HRAS, KRAS et NRAS, les trois principaux homologues de la protéine RAS, sont principalement mutées au niveau des codons 12, 13 ou 61. Les mutations avec un effet de gain de fonction au niveau de ces codons rendent ces protéines RAS constitutivement actives et sont à l’origine des signaux hyperprolifératifs. Depuis la découverte de la protéine RAS, de nombreuses "protéines effectrices RAS" agissant en aval ont été identifiées. Le rôle biologique de la plupart de ces effecteurs RAS est lié à la prolifération et à la survie des cellules. Cependant, au cours des deux dernières décennies une nouvelle famille d'effecteurs RAS, les protéines RASSF, a été découverte comme ayant une fonction pro-apoptotique. Les protéines suppresseures de tumeurs de la famille RASSF sont fréquemment inhibées dans les cellules cancéreuses humaines. Il existe 10 homologues de RASSF (RASSF1-10) chez humain, chacun comprenant un domaine d'association RAS (RA) impliqué dans la liaison avec les GTPases RAS. Plusieurs RASSF comportent également les domaines SARAH (Salvador-RASSF-Hippo), connus pour interagir avec les kinases Hippo contenant aussi les domaines SARAH. On ne sait toutefois pas si toutes les protéines RASSF sont de véritables effecteurs RAS. Il a été démontré qu'un seul membre de la famille RASSF, appelé RASSF5, s'associe directement à HRAS et cette interaction a été validée par des études cristallographiques à rayons X. Dans la première partie de cette thèse, je démontre qu'aucun autre membre de la famille RASSF n'interagit directement avec KRAS. En me servant de la modélisation par l'homologie du domaine RA hautement apparenté de RASSF1, j’ai identifié les acides aminés essentiels pour l’interaction avec la GTPase. Je démontre que la substitution d’un seul acide aminé dans la protéine RASSF1 permet l'interaction avec KRAS, et je pose l'hypothèse que ce résidu, ayant divergé au cours de l'évolution, a modifié la spécificité de RASSF1 pour les petites GTPases. En utilisant une approche informatique, nous avons prédit six GTPases candidates que pourraient interagir avec RASSF1 : GEM, REM1, REM2, RASL12, ERAS et DIRAS3. J'ai validé les interactions avec plusieurs GTPases RGK (GEM, REM1, REM2) et j’ai démontré que la co-expression des GTPases RGK avec RASSF1 active la voie Hippo. Ainsi, je propose un nouveau lien entre ces GTPases peu étudiées et la régulation de la voie de signalisation Hippo. Dans la deuxième partie de ma thèse, je tente de rediriger la signalisation de prolifération cellulaire de KRAS (RAF/MAPK) vers une signalisation impliquant les effecteurs pro-apoptotiques (RASSF-Hippo). Pour y parvenir, j'ai conçu des mutations dans KRAS dans le but d’augmenter son affinité pour RASSF5 et d’affaiblir son interaction avec BRAF. Comme deuxième stratégie, j'ai remplacé les résidus divergents de l'effecteur RASSF1 par les résidus correspondants de RASSF5 et j’ai démontré que cette variante de RASSF1 est capable de lier KRAS. Diverses approches biophysiques et biochimiques ont été utilisées pour valider KRAS et RASSF1 mutés, impliquées dans cette signalisation redirigée. Les études de co-localisation montrent que ces mutants interagissent avec leurs nouveaux partenaires comme prévu. D’autre part, je démontre par les expériences intracellulaires que KRAS modifiée ne lie plus BRAF tout en interagissant fortement avec RASSF5 et RASSF1, et que les mutants établis activent la voie Hippo. Ainsi, j'ai développé deux approches qui nous aideront à étudier la signalisation de KRAS dans la voie pro-apoptotique impliquant RASSF en absence de l’activation de la voie des MAP kinases. Les données présentées ici nous permettent de mieux comprendre la manière dont les protéines RASSF ont divergé au cours de l'évolution; cette divergence leur empêchant d’interagir avec les RAS. Ces données fournissent également une stratégie innovante pour rediriger les signaux RAS vers les effecteurs RASSF, qui pourrait être utilisée comme nouvelle stratégie dans les études cliniques utilisant RAS comme cible thérapeutique. / RAS small GTPases function as molecular switches to transduce signals from cell surface receptors to various downstream signalling networks. The RAS protein has roles in multiple biological functions, including cell proliferation, survival, and even apoptosis. Mutations in RAS genes are present in up to 30% of all human tumors. The three major RAS homologs HRAS, KRAS, and NRAS are each found mutated, predominantly at codons 12, 13 or 61. Gain-of-function mutations at these codons render these RAS proteins constitutively active and thereby produce hyperproliferative signals. Since the discovery of RAS, numerous downstream ‘RAS effector proteins’ have been identified. The biological role of most identified RAS effectors relates to cell proliferation and survival, however, in the past two decades a new family of RAS effectors, RASSF proteins, were discovered to have a pro-apoptotic function. The RASSF family of tumor suppressors proteins are frequently downregulated in human cancer cells. There are 10 RASSF homologs (RASSF1-10) in humans, each comprising a RAS association (RA) domain presumed to bind RAS GTPases. RASSF also encode SARAH (Salvador-RASSF-Hippo) domain, known to interact with SARAH-containing Hippo kinases. It is not clear whether all the RASSF proteins are true RAS effectors. Only a single family member, RASSF5, has been shown to directly associate with HRAS and this interaction has been completely validated by X-Ray crystallographic studies. In the first part of this thesis, I demonstrate that no other RASSF family members directly interact with KRAS. I used homology modelling of the highly related RASSF1 RA domain to identify amino acids crucial to GTPase binding. I show that a single amino acid substitution in RASSF1 enables interaction with KRAS, and hypothesize that this evolutionarily diverged residue has altered RASSF1 specificity for small GTPases. Using an informatics approach, we predicted six candidate GTPases that could interact with RASSF1: GEM, REM1, REM2, RASL12, ERAS and DIRAS3. I validated interactions with several RGK GTPases (GEM, REM1, REM2) and show that co-expression of RGK GTPases with RASSF1 activates the Hippo pathway. Thus, I show a novel link between these unstudied GTPases to Hippo pathway regulation. In the second part of my thesis I attempt to rewire KRAS signalling from cell proliferation pathways (RAF/MAPK) to pro-apoptotic effectors (RASSF-Hippo). To achieve this, I designed mutations in KRAS that augmented its affinity for RASSF5 and weakened interaction with BRAF. As a second strategy, I reverted evolutionarily diverged residues in the RASSF1 effector to corresponding residues in RASSF5 and demonstrate that this variant now binds KRAS. Various biophysical and biochemical approaches were used to validate both the KRAS and RASSF1 rewired mutants, and co-localization studies show that these mutants interact with their new binding partners as predicted. Further, I demonstrate that our rewired KRAS no longer binds BRAF in cells but interacts strongly with RASSF5 and rewired RASSF1, and that the rewiring mutants activate the Hippo pathway. Thus, I have developed two rewiring approaches that will help us to study KRAS signalling towards pro-apoptotic RASSF pathway in the absence of strong MAP kinase activation. The data presented here provide several novel insights into how RASSF proteins diverged through evolution and are not all direct effectors of RAS. In addition, I present an innovative rewiring strategy to couple RAS signals towards RASSF effectors which can be a clinical tactic to target RAS oncogenesis.

No description available.

No description available.